Trial · NCT01724021
Results by group112
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 112
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6 | Arm A | 79.1 | 95% Confidence Interval 74.2 to 83.5 | percentage of participants | |
| Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6 | Arm B | 80.6 | 95% Confidence Interval 75.7 to 84.8 | percentage of participants | |
| Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8 | Arm A | 77.1 | 95% Confidence Interval 71.9 to 81.8 | percentage of participants | |
| Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8 | Arm B | 84.2 | 95% Confidence Interval 79.6 to 88.2 | percentage of participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) | Arm A | 352 | participants | ||
| Number of Participants With Treatment Emergent Adverse Events (AEs) | Arm B | 347 | participants | ||
| Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV]) | Rituximab Intravenous (IV) | 840 | Full Range 0 to 3967.0 | minutes | |
| Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV]) | Rituximab Subcutaneous (SC) | 22 | Full Range 0 to 1242.0 | minutes | |
| Cancer Therapy Satisfaction Questionnaire (CTSQ) Score | Rituximab Intravenous (IV) | Expectations of therapy domain | 80.88 | Standard Deviation 18.315 | units on a scale |
| Cancer Therapy Satisfaction Questionnaire (CTSQ) Score | Rituximab Subcutaneous (SC) | Expectations of therapy domain | 82.07 | Standard Deviation 17.817 | units on a scale |
| Cancer Therapy Satisfaction Questionnaire (CTSQ) Score | Rituximab Intravenous (IV) | Feelings about side effects domain | 60.63 | Standard Deviation 22.316 | units on a scale |
| Cancer Therapy Satisfaction Questionnaire (CTSQ) Score | Rituximab Subcutaneous (SC) | Feelings about side effects domain | 61.64 | Standard Deviation 22.324 | units on a scale |
| Cancer Therapy Satisfaction Questionnaire (CTSQ) Score | Rituximab Intravenous (IV) | Satisfaction with therapy domain | 84.59 | Standard Deviation 12.218 | units on a scale |
| Cancer Therapy Satisfaction Questionnaire (CTSQ) Score | Rituximab Subcutaneous (SC) | Satisfaction with therapy domain | 85.42 | Standard Deviation 11.259 | units on a scale |
| Rituximab Administration Satisfaction Questionnaire (RASQ) Score | Rituximab Intravenous (IV) | Physical impact domain | 82.14 | Standard Deviation 15.629 | units on a scale |
| Rituximab Administration Satisfaction Questionnaire (RASQ) Score | Rituximab Subcutaneous (SC) | Physical impact domain | 82.08 | Standard Deviation 15.882 | units on a scale |
| Rituximab Administration Satisfaction Questionnaire (RASQ) Score | Rituximab Intravenous (IV) | Psychological Impact domain | 77.73 | Standard Deviation 16.377 | units on a scale |
| Rituximab Administration Satisfaction Questionnaire (RASQ) Score | Rituximab Subcutaneous (SC) | Psychological Impact domain | 84.00 | Standard Deviation 14.358 | units on a scale |
| Rituximab Administration Satisfaction Questionnaire (RASQ) Score | Rituximab Intravenous (IV) | Impact on activitiesf daily living | 59.49 | Standard Deviation 22.233 | units on a scale |
| Rituximab Administration Satisfaction Questionnaire (RASQ) Score | Rituximab Subcutaneous (SC) | Impact on activitiesf daily living | 81.86 | Standard Deviation 15.844 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01724021/results